Summit Hotel Properties Announces Q3 AFFO of 17c, Exceeding Consensus Estimate of 14c
Q3 Financial Performance: The company reported Q3 revenue of $177.12M, slightly above the consensus of $176.6M, but experienced a 3.7% decrease in same store RevPAR to $115.77 compared to Q3 of 2024.
Operating Trends: Despite challenges such as reduced government demand and slower international travel impacting average daily rates, the company managed to grow market share, with a RevPAR index increase of 140 basis points to approximately 116%.
Cost Management: The disciplined approach to cost management resulted in pro forma operating expenses increasing by less than 2% during the quarter and just over 1.5% year-to-date.
Future Outlook: The company anticipates sequential improvement in operating trends for Q4 and maintains a positive long-term outlook due to expected benefits from a lack of new supply growth in the industry.
Get Free Real-Time Notifications for Any Stock
Analyst Views on INN
About INN
About the author

Innocan Pharma Anticipates NYSE Listing with Concurrent Offering
- Listing Plans: Innocan Pharma anticipates listing on NYSE American around January 30, 2026, contingent upon approval of its application and compliance with exchange rules, which will provide the company with broader access to capital markets.
- Concurrent Offering: The company is conducting a concurrent offering of its securities, with details to be disclosed through filings with the SEC and SEDAR+, expected to enhance the company's liquidity and market recognition.
- Trading Transition: Following the NYSE listing, trading of Innocan's common shares on OTCQB will terminate around January 29, 2026, a transition that is expected to improve the company's image and liquidity among investors.
- Business Development: Innocan's innovations in pharmaceuticals and wellness, particularly its CBD-loaded liposome drug delivery platform, are anticipated to further drive market share growth by addressing the demand for non-opioid pain management solutions.

Summit Hotel Properties (INN) Declares $0.08 Cash Dividend with 6.6% Annual Yield
- Dividend Announcement: Summit Hotel Properties has declared a cash dividend of $0.08 per share for Q4 2025, reflecting a 6.6% annualized yield based on the closing price on January 21, 2026, indicating the company's strong cash flow and commitment to shareholder returns.
- Preferred Stock Dividends: The company will also pay a dividend of $0.390625 per share for its 6.25% Series E Preferred Stock and $0.3671875 for its 5.875% Series F Preferred Stock, enhancing its appeal to preferred stock investors.
- Operating Partnership Distribution: Authorized cash distributions include $0.328125 per unit for the 5.25% Series Z Preferred Units, demonstrating the company's flexibility in financing structures and commitment to its investors.
- Portfolio Overview: As of January 22, 2026, Summit Hotel's portfolio consists of 95 properties with 14,348 guestrooms across 24 states, showcasing its strong competitive position and market penetration in the upscale hotel sector.









